Zuletzt aktualisiert: August 17, 2026
Cell-Based Immunotherapy Products
Abecma
BLUEBIRD BIO
A chimeric antigen receptor (AUTO) T-cell therapy for adults with relapsed or refractory multiple myeloma. Approved by the US FDA in March 2021. Approved by Health Canada in May 2021. Approved by the EMA in August 2021. Approved for use in Japan in February 2022.
APCeden
APAC BIOTECH
APCeden is an autologous monocyte-derived mature dendritic cell vaccine. It was approved in India in 2017 for the treatment of prostate cancer, ovarian cancer, colorectal cancer, and Non Small Cell Lung carcinoma.
Breyanzi
BRISTOL MYERS SQUIBB
Breyanzi is a CAR T-cell therapy for adults with relapsed or refractory large B-cell lymphoma. It is approved by the US FDA for adult patients with relapsed or refractory diffuse large B-cell lymphoma (Februar 2021), and again for r/r large B-cell lymphoma as second line treatment (Juni 2022). It is approved by the European Commission for use in adult patients with r/r large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B (April 2022).
Carteyva
JW THERAPEUTICS
Carteyva is an autologous anti-CD19 CAR-T cell immunotherapy drug. It was approved by China’s NMPA in 2021 to treat adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Carvykti
LEGEND BIOTECH & JANSSEN
Carvykti is a CAR-T cell therapy used for adult patients who have cancer of the bone marrow called multiple myeloma. It was approved in the U.S. in February of 2022 to treat relapsed or refractory multiple myeloma after four or more prior lines of therapy. It was also approved in the European Union in May of 2022 to treat relapsed or refractory multiple myeloma for adult patients who received at least three prior therapies.
CreaVax RCC
JW CREAGENE
A dendritic cell based vaccine intended to treat metastatic renal cell carcinoma for which nephrectomy can be performed. Zugelassen in S. Korea in S. Korea in 2007.
Immuncell-LC
GC PHARMA
A medicine for anticancer cell immunotherapy, made with T-lymphocyte incubated and activated after extraction from the blood of a patient. Bedingt zugelassen in S. Korea in June 2007.
Kymriah
NOVARTIS
Kymriah is a CAR T-cell therapy product approved in the US for the treatment of acute lymphoblastic leukemia (ALL), chronic lymphoid leukemia and diffuse large B-cell lymphoma in patients up to 25 Jahre alt, (US-amerikanische FDA, August 2017) the treatment of adult patients with relapse/refractory (r/r) large B-cell lymphoma, (US-amerikanische FDA, Mai 2018) and the treatment of adult patients with (r/r) follicular lymphoma. (US-amerikanische FDA, Mai 2022)
It also received EU marketing authorisation for these indications by the European Commission in August 2018, and by Health Canada in September 2018.
It was approved in Japan for the treatment of ALL in February 2019 and in Singapore in 2021.
Provenge
DENDREON
Autologous Cellular Immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. BLA approved by the FDA in 2010.
Tecartus
KITE, A GILEAD COMPANY
Tecartus is a CAR-T therapy designed to treat mantle cell lymphoma. It was approved in the US in July 2020 and in the EU in December 2020.
Yescarta
KITE, A GILEAD COMPANY
Yescarta is a CAR T-cell therapy product indicated for the treatment of B cell malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, mantle cell lymphoma, chronic lymphoid leukemia and diffuse large B-Cell lymphoma. Von den USA zugelassen. FDA in October 2017. Approved by the EC in August 2018. Approved by Health Canada in February 2019. Approved in Japan in January 2021, and in China in June 2021.
Yescarta was approved for additional indications to treat follicular lymphoma (US-amerikanische FDA, Marsch 2021) and r/r large B-cell lymphoma (US-amerikanische FDA, April 2022). It was also approved for additional indications to treat r/r follicular lymphoma (EU, Juni 2022) in the European Union.
Wissenschaftliche Fallbesprechung
Möchten Sie verstehen, ob aktuelle klinische Programme, aktuelle Forschungsentwicklungen, oder neue Ansätze können sein relevant für Ihre individuelle Situation?
Senden Sie Ihre Frage an unser wissenschaftliches Team. Der Hauptsitz von NBScience im Vereinigten Königreich koordiniert Anfragen im internationalen Netzwerk medizinischer Zentren, Wissenschaftler, und spezialisierte Berater.
- Überprüfung der von Ihnen bereitgestellten Informationen
- Relevante Informationen zu Forschung und klinischen Programmen
- Eine klare Antwort, die sich auf Ihre Situation konzentriert
Keine Verpflichtung. Ihre Frage wird vertraulich behandelt.
Nur Bildungs- und Forschungsinformationen. Dieser Dienst funktioniert nicht stellen eine medizinische Beratung dar, Diagnose, Rezept, oder eine personalisierte Behandlungsempfehlung.
